Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) CFO Gabriel Morris acquired 1,418 shares of Immix Biopharma stock in a transaction on Wednesday, November 18th. The stock was purchased at an average cost of $7.06 per share, with a total value of $10,011.08. Following the completion of the transaction, the chief financial officer directly owned 292,847 shares in the company, valued at $2,067,499.82. This represents a 0.49% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Immix Biopharma Stock Performance
NASDAQ:IMMX opened at $6.96 on Friday. Immix Biopharma, Inc. has a 52 week low of $3.78 and a 52 week high of $15.10. The firm has a 50-day moving average price of $9.25 and a two-hundred day moving average price of $9.61. The firm has a market cap of $583.32 million, a price-to-earnings ratio of -8.39 and a beta of 0.29.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). As a group, sell-side analysts forecast that Immix Biopharma, Inc. will post -0.75 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on IMMX shares. Mizuho dropped their price target on Immix Biopharma from $23.00 to $22.00 and set an “outperform” rating on the stock in a report on Wednesday. Morgan Stanley upped their price objective on Immix Biopharma from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, October 15th. Needham & Company LLC raised their target price on Immix Biopharma from $21.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Finally, HC Wainwright lifted their target price on Immix Biopharma from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, November 16th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immix Biopharma has a consensus rating of “Moderate Buy” and an average price target of $24.14.
View Our Latest Analysis on Immix Biopharma
Institutional Investors Weigh In On Immix Biopharma
Several large investors have recently added to or reduced their stakes in IMMX. Jupiter Topco LLC bought a new stake in Immix Biopharma in the 2nd quarter valued at about $100,816,000. Janus Henderson Group PLC boosted its position in Immix Biopharma by 22.5% during the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after purchasing an additional 880,434 shares during the period. BlackRock Inc. bought a new position in Immix Biopharma during the second quarter worth about $30,827,000. Opaleye Management Inc. bought a new position in Immix Biopharma during the second quarter worth about $24,177,000. Finally, Marshall Wace LLP increased its stake in shares of Immix Biopharma by 3.3% in the third quarter. Marshall Wace LLP now owns 1,854,215 shares of the company’s stock worth $19,284,000 after purchasing an additional 59,307 shares in the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.
Immix Biopharma Company Profile
Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.
Recommended Stories
- Five stocks we like better than Immix Biopharma
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
